Psychedelic Science 2017: A Conversation with MAPS Executive Director, Rick Doblin PhD

Rick Doblin is the founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS), a 501c3 nonprofit organization dedicated to developing psychedelics and marijuana into prescription medicines. Currently MAPS is preparing for FDA-approved Phase 3 Clinical Trials examining the safety and efficacy of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD), these are the final round of studies before requesting approval as a FDA-approved treatment, which is anticipated for 2021.

In today's show, we hope discuss a wide range of topics in the field of psychedelic medicine, including:

• Therapeutic applications of psychedelics & marijuana
• Creative, spiritual and personal growth potential of psychedelics & marijuana
• Regulatory challenges of studying schedule 1 substances
• Tiimeline for MDMA-assisted psychotherapy approval as a prescription treatment
• Psychedelic harm reduction and moving toward a post-prohibition world
• The Psychedelic Science 2017 conference, a six-day international gathering featuring three days of conference programming, three full days of workshops, the top experts in the field, and so much more.